ER (Estrogen receptor)

P3, N=463, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jan 2027 --> Mar 2028

P=N/A, N=305, Completed, Thomas Jefferson University | Active, not recruiting --> Completed

P=N/A, N=2000, Recruiting, National and Kapodistrian University of Athens

The combination of ΔDCEUS% and ΔEmax% demonstrated superior predictive ability for NAC response, with an area under the curve (AUC) of 0.906, outperforming ΔDCEUS% (AUC 0.871) or ΔEmax% (AUC 0.722) alone. CEUS combined with SWE shows promise for predicting pCR in invasive breast cancer undergoing NAC.

P1/2, N=24, Not yet recruiting, University of Chicago

Here, we evaluated targeting candidates from this signature KMT5B/C and IKBKE using inhibitors A-196 and IKBKEi respectively, alongside anti-estrogen (fulvestrant) and a TGFβ blocking antibody (NIS793), both individually and in combination with αPD-L1, within this rat model. Comprehensive tumor profiling through polychromatic flow cytometry and single-cell RNA sequencing revealed that A-196 induced a luminal-to-basal shift in tumor epithelial cells, enhancing antigen presentation, whereas epithelial-to-mesenchymal transition was linked to fulvestrant resistance. Our findings underscore the value of the rat mammary tumor model for preclinical studies in ER-positive breast cancer and advocate for the further validation and potential clinical development of KMT5B/C inhibitors to enhance the efficacy and broaden the applicability of ICI therapy in cancer patients.

These data provide an expanded understanding of the molecular underpinnings of EMCG-including the first description of a SMARCA4 frameshift variant in this entity-and demonstrate that while gastrointestinal marker immunoexpression is relatively common among endometrial carcinomas, strictly defined EMCG remains rare (<1%). As awareness of this entity grows, pathologists should take care not to over-interpret gastrointestinal marker expression as stand-alone evidence of an EMCG diagnosis.

S.J.L. received funding from an NHMRC Project Grant ID: 1125433.

The pronounced effects in AA-derived ER- spheroids align with known disparities in tumor aggressiveness and suggest future NOHA clinical utility potential in racially diverse populations. Further in vivo validation is warranted to support and confirm such clinical translation.

Despite peritoneal carcinomatosis, the patient responded to cisplatin/gemcitabine chemotherapy and immunotherapy, demonstrating tumor shrinkage on follow-up imaging. This case highlights the diagnostic challenges of SRCC due to its nonspecific symptoms and potential histological overlap with other metastatic gastrointestinal tumors. Early recognition and a multidisciplinary approach are critical for improving patient outcomes.

P2, N=107, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

Overall, Gouania longipetala aqueous extract exhibit selective activity on estradiol-sensitive tissues in vivo and, various effects against breast cancer cell proliferation and estradiol-induced proliferative effects in vitro. All taken into account, GLO may have a notably importance as therapeutic agent used in chemotherapy against E2-dependent cancer.